
An older but still common multiple sclerosis (MS) treatment has an unexpected perk: It not only quells symptoms, but patients may also live longer. New research revealed that patients taking a beta interferon drug for more than three years were likely to live longer than those who took one for a shorter time or who didn’t take one at all. “This study was the first and largest of its kind, and we found that a commonly used drug for MS may prolong life,” said the study’s senior author, Helen Tremlett. She’s the Canada Research Chair in Neuroepidemiology and Multiple Sclerosis at the University of British Columbia in Vancouver, Canada. Beta interferon drugs include Avonex, Betaseron, Extavia, Plegridy and Rebif. Beta interferons were the first disease-modifying drugs available to treat MS. They were introduced in the 1990s to treat relapsing MS. Newer medications are now available, but beta interferons are still widely used, the study authors noted. Multiple sclerosis is a chronic disease that affects the central nervous system. The symptoms include muscle weakness, trouble with coordination and balance, visual disturbances and problems with thinking and memory. MS can shorten life span an average of six years or more, the study authors said. Dr. Nicholas LaRocca is vice president of Health Care Delivery and Policy Research for the National Multiple Sclerosis Society. He explained that, in… read on >